Actively Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Led by Nurix Therapeutics, Inc. · Updated on 2026-04-14
100
Participants Needed
20
Research Sites
258 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
CONDITIONS
Official Title
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed relapsed or refractory CLL/SLL meeting diagnostic and treatment criteria
- ECOG performance status between 0 and 2
- Prior treatment with covalent and non-covalent BTK inhibitors and a BCL-2 inhibitor
- Measurable disease by imaging
- Adequate organ and bone marrow function
- Signed informed consent indicating understanding and willingness to participate
You will not qualify if you...
- Known or suspected prolymphocytic leukemia or Richter's transformation before enrollment
- Use of investigational or anticancer therapy within 5 half-lives or 14 days before study drug start
- Antibody therapy must have stopped at least 4 weeks before study drug
- No other systemic anticancer therapy allowed during study except certain hormonal therapies
- Radiotherapy within 2 weeks before study drug start except for palliative radiation
- Use of systemic corticosteroids above 20 mg/day prednisone or equivalent within 7 days before study drug start except for premedication
- Use of systemic immunosuppressive drugs other than corticosteroids within 60 days before study drug start
- Previous treatment with a BTK degrader
- CAR T-cell therapy or autologous hematopoietic cell transplant within 1 year before enrollment
- Thromboembolic events, stroke, or intracranial hemorrhage within 6 months before study drug start
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Colorado Blood Institute
Denver, Colorado, United States, 80218
Actively Recruiting
2
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
3
University of Iowa
Iowa City, Iowa, United States, 52242
Actively Recruiting
4
Maryland Oncology Hematology
Silver Spring, Maryland, United States, 20904
Actively Recruiting
5
Novant Health Cancer Institute
Winston-Salem, North Carolina, United States, 27103
Actively Recruiting
6
University of Cincinnati
Cincinnati, Ohio, United States, 45221
Actively Recruiting
7
Oncology Hematology Care
Fairfield, Ohio, United States, 45014
Actively Recruiting
8
SCRI Oncology Partners
Nashville, Tennessee, United States, 37203
Actively Recruiting
9
Texas Oncology - Center South
Austin, Texas, United States, 78705
Actively Recruiting
10
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States, 22031
Actively Recruiting
11
Virginia Oncology Associates
Norfolk, Virginia, United States, 23502
Actively Recruiting
12
CHU de Nantes
Nantes, France, 44000
Actively Recruiting
13
AUSL della Romagna UO Ematologia
Ravenna, Italy, 48121
Actively Recruiting
14
Pratia Hematologia Sp. z o.o.
Katowice, Poland, 40-519
Actively Recruiting
15
Pratia S.A.
Krakow, Poland, 30-225
Actively Recruiting
16
Aidport Sp. z o.o.
Skorzewo, Poland, 60-185
Actively Recruiting
17
Pratia Warszawa / Pratia MTZ
Warsaw, Poland, 02-172
Actively Recruiting
18
Oxford University Hospitals NHS Foundation Trust
Headington, Oxford, United Kingdom, OX3 9D
Actively Recruiting
19
The Royal Marsden NHS Foundation Trust
London, United Kingdom, SW3 6JJ
Actively Recruiting
20
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
A
Additional Site Contact Information
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here